Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a Notice of Compliance from Health Canada for its biosimilar Dyrupeg. The regulatory nod confirms the drug meets safety and quality ...
ET Now on MSN
Aurobindo Pharma’s arm CuraTeQ Biologics receives Health Canada NOC for cancer drug biosimilar Dyrupeg
Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received Health Canada’s compliance notice for its biosimilar ...
Aurobindo Pharma's CuraTeQ Biologics receives Health Canada approval for Dyrupeg, marking a major regulatory milestone for ...
Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received a Notice of Compliance from Health Canada for its ...
Samsung Biologics, a biotechnology company based in South Korea, announced plans to open its first U.S. manufacturing ...
Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Phase 3 trial of VCN-01 for ...
Investment (INV072135) continues the support for selected Gates Foundation grantees to improve the developability and reduce the cost of goods of monoclonal antibodies to make them more affordable and ...
As of Tuesday, January 06, AbCellera Biologics Inc.’s ABCL share price has surged by 6.71%, which has investors questioning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback